Device Trial Radar · NCT05867407
A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11,610
Actual
Start
Jun 13, 2024
Primary completion
May 30, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- Anumana, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Mayo Clinic
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, cluster-randomized, care-as-usual controlled trial to evaluate the impact of an ECG-based artificial intelligence (ECG-AI) algorithm to detect low left ventricular ejection fraction (LVEF) on diagnosis rates of LVEF ≤ 40% in the outpatient setting. The objective of this study is to evaluate the impacts of an ECG-AI algorithm to detect low LVEF and an associated Medical Device Data System when used during routine outpatient care. The study will be conducted in 2 phases: feasibility assessment phase and clinical impact phase.
Conditions
- Ventricular Ejection Fraction
Interventions
Anumana Low EF AI-ECG AlgorithmDevice
Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
Care-as-UsualOther
Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnosis rates of low ejection fraction of less than or equal to 40 percent by echocardiography compared to care-as-usualTime frame: 90 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
Mayo Clinic Florida
Jacksonville, Florida
Mayo Clinic Rochester
Rochester, Minnesota
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.